Standard titration protocol from clinical trials The Phase 2 NEJM trial used the following escalation schedule for the 12 mg dose group: Weeks 1 through 4: 2 mg once weekly (subcutaneous) Weeks 5 through 8: 4 mg once weekly Weeks 9 through 12: 8 mg once weekly Week 13 and beyond: 12 mg once weekly (maintenance dose) For the 8 mg target dose, the schedule was: Weeks 1 through 4: 2 mg once weekly Weeks 5 through 8: 4 mg once weekly Week 9 and beyond: 8 mg once weekly (maintenance dose) These titration schedules are not suggestions
While also meeting criteria for later fibromyalgia may be rare among patients treated promptly for early Lyme disease as a whole (1%) (87), earlier studies suggested that this overlap may be more common among the subset of patients with prolonged, persistent symptoms (8991)
Its also helpful for people recovering from illness, high stress, or taking medications that affect nutrient absorption
Always verify local laws before ordering
It is also one of the three actives in the Peptual transdermal patch he endorses, alongside BPC-157 and NAD+: BPC-157: ~2000 mcg NAD+: ~250 mg GHK-Cu: ~10 mg The patch combines tissue repair (BPC-157), cellular energy (NAD+), and collagen synthesis (GHK-Cu) in a sustained-release format (source)
